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1
OPIOID-NORNICOTINE CODRUGS
COMBINATIONS FOR PAIN MANAGEMENT

This application claims priority from U.S. Provisional
Patent Application No. 61/072,091, filed Mar. 27, 2008, the
disclosure of which is hereby incorporated by reference in its

m

entirety.

whereinY is O or S; R1 is an opioid moiety; and R2-N?R3
is a nornicotine moiety; or

FIELD OF THE INVENTION

The present invention relates to the field of pain manage

O

H
N

X

Rl/ T T \R2

ment, and more particularly to synergistic codrugs compris
ing an opioid and nomicotine which have been combined to

O

form a single chemical codrug entity. When the codrug is
administered it produces a synergistic analgesic response to

O

wherein X is nothing, O, S, NH, NR4 (where R4:alkyl),
(CH2),C (where X11-20, and alkyl is linear or branched), and

pain.
BACKGROUND OF INVENTION

20

nornicotine moiety.
In another embodiment, the present invention provides a
method of of synthesis of a codrug comprising a linker, an

Opioids are any endogenous or exogenous compounds that
bind to an opioid receptor. Opioid receptors are localiZed

primarily in the brain, spinal cord, and gastrointestinal tract.

wherein Rl-O is an opioid moiety and R2-N?R3 is a

opioid and a nornicotine, said method comprising: a)
25

covalently bonding a first attachment point ofthe linker to the

opioid; b) covalently bonding a second attachment point of
the linker to the nornicotine; and c) recovering the codrug,

When opioids bind to their receptors in the brain and spinal

cord they block pain transmission signals from the periphery

wherein the nornicotine is selected from the group consisting
of S-nornicotine, R-nomicotine, and racemic nornicotine.
In another embodiment, the present invention provides a

of the body. Although opioids are very effective for moderate
to severe pain, there are many well known problems associ

ated with opioid therapy. Those problems include serious side

method of treatment comprising: joining an opioid together

effects such as cognitive dysfunction, respiratory depression,
nausea/vomiting, urinary retention, and constipation. Fur
ther, chronic opioid therapy often results in the development

with a nornicotine using a linker to form a cleavable codrug;
and administering an analgesically effective amount of the
codrug to a humanpatient, wherein the nornicotine is selected

of tolerance to the analgesic effect, resulting in dose escala
tion, as well as physical and psychological dependence.

and racemic nornicotine.

from the group consisting of S-nornicotine, R-nomicotine,

Nornicotine, the primary metabolite of nicotine, binds to
nicotinic receptors which are located in the brain, spinal cord

and periphery (autonomic ganglia and smooth muscle). It has
recently been appreciated that nicotinic receptor binding can
also modulate pain signals to the brain suggesting their poten

BRIEF DESCRIPTION OF THE DRAWINGS
40

FIG. 2 is a graph illustrating the effect of S-normcotine

tial use in the treatment of pain (acute, chronic, cancer-re

(S-NNIC) and morphine (MOR) combinations mechanical

lated).

hyperalgesia.

There is a great need for analgesic medications able to

FIG. 3 shows codrug of 3-acetylmorphine and S-nomico
tine of GC-MS of acetyl morphine.
FIG. 4 shows H-NMR analysis of acetyl morphine.
FIG. 5 shows C-NMR of acetyl morphine.

provide high eñicacy pain relief while providing more favor
able pharmacokinetics and reducing the possibility of unde
sirable effects. Enhancement of the analgesic effect of opio
ids as well as nornicotine has been described in the art

FIG. 1 is a graph illustrating the effect of S-normcotine

(S-NNIC) and morphine (MOR) combinations thermal anti
nociception, using the tail flick test.

50

FIG. 6 shows ESI-MS of the para-nitrophenoxycarbamate

Therefore, there is a need for a way to administer opioids and
nornicotine to provide a more favorable pharmacokinetic pro
file.

ester of codeine.

SUMMARY OF THE INVENTION

ester of codeine.

FIG. 7 shows H-NMR analysis of the para-nitrophenoXy
carbamate ester of codeine.

FIG. 8 shows C-NMR of the para-nitrophenoxycarbamate
FIG. 9 shows H-NMR of an acetyl morphine and S-norm

cotine codrug.

The present invention provides a codrug of the following

FIG. 10 shows C-NMR of an acetyl morphine and S-nor

formula:

nicotine codrug.
60

Opioid

Nomicotine

65

as well as pharmaceutical compositions thereof. The linker
may be

FIG. 11 shows H-NMR analysis of an intermediate in the
preparation of a codrug of codeine and S-nomicotine.
FIG. 12 shows C-NMR analysis of an intermediate in the
preparation of a codrug of codeine and S-nomicotine.
FIG. 13 shows MALDI analysis of an intermediate in the
preparation of a codrug of codeine and S-nomicotine.
FIG. 14 shows H-NMR analysis of a codrug of codeine and
S-nomicotine.

